At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Gefapixantdrug
Likely dose
Gefapixant 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Tolerability of a Single Dose of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Jun 23, 2015·Updated Jun 25, 2019
In Brief
A Phase 2 clinical trial evaluating Gefapixant for Idiopathic Pulmonary Fibrosis. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study assesses the tolerability of a single dose of gefapixant (AF-219) in participants with idiopathic pulmonary fibrosis (IPF). Six eligible participants will receive a single 150 mg dose of gefapixant and undergo tolerability and PK assessments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJul 2015
Primary CompletionAug 2015
Study CompletionAug 2015
TodayJul 2026
First PostedJun 23, 2015
Enrollment StartJul 20, 2015
Primary CompletionAug 7, 2015
Study CompletionAug 21, 2015
TodayJul 2, 2026
Enrollment to primary: 17 daysPosted 11.0 years ago
Interventions
Gefapixantdrug
Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only